Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MBIO
DateTimeSourceHeadlineSymbolCompany
01/17/20254:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/15/20253:17PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
01/14/20257:00AMGlobeNewswire Inc.Mustang Bio Announces Reverse Stock SplitNASDAQ:MBIOMustang Bio Inc
01/10/20254:09PMEdgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:MBIOMustang Bio Inc
01/10/20254:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/02/20253:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
12/06/20244:00PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBIOMustang Bio Inc
12/02/20243:45PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
11/28/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBIOMustang Bio Inc
11/22/20243:45PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
11/15/20243:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/12/20247:30AMGlobeNewswire Inc.Mustang Bio Receives Positive Listing Determination from NasdaqNASDAQ:MBIOMustang Bio Inc
11/08/20243:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
11/07/20247:30AMGlobeNewswire Inc.Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaNASDAQ:MBIOMustang Bio Inc
11/06/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
10/29/20243:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
10/25/20243:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
10/24/20241:10PMGlobeNewswire Inc.Mustang Bio Announces Exercise of Warrants for $4 Million Gross ProceedsNASDAQ:MBIOMustang Bio Inc
09/13/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
08/16/20244:08PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
08/13/20243:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
07/29/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBIOMustang Bio Inc
07/19/20244:26PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
07/10/20243:41PMEdgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:MBIOMustang Bio Inc
06/21/20243:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
06/20/20247:00AMGlobeNewswire Inc.Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
06/20/20247:00AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
06/17/20247:30AMGlobeNewswire Inc.Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyNASDAQ:MBIOMustang Bio Inc
06/12/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBIOMustang Bio Inc
06/06/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
 Showing the most relevant articles for your search:NASDAQ:MBIO